Sarah Yentz is an Oncology physician affiliated with University of Michigan. OpenAlex indexes 51 publications with 677 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 East Medical Center Dr
B1 Floor Cancer Recp D
Ann Arbor, MI 481095913
Telephone
734-647-8903Registry record last updated 17 Jan 2019.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
22.6%Corticosteroid15.9%Prednisone100%Part D≥37 patientsProton pump inhibitor3.5%Omeprazole100%Part D≥12 patients+ 1 more class in this area
Cancer & immunology
17.6%Cytochrome P450 17A1 Inhibitor13.8%Abiraterone Acetate100%Part D≥13 patientsKinase inhibitor3.8%Cabometyx100%Part D<11 patientsNervous system
17.3%Opioid Agonist7.5%Oxycontin27%Oxycodone Hcl25%Tramadol Hcl-Acetaminophen25%Morphine Sulfate Er23%Part D<11 patientsSNRI3.6%Duloxetine Hcl100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- ICON trial: Phase I/II trial of inulin gel in combination with ipilimumab and nivolumab in advanced renal cell.
Journal of Clinical Oncology
2026 - Impact of abiraterone versus enzalutamide on depression and anxiety in hormone-sensitive prostate cancer (HSPC).
Journal of Clinical Oncology
2026 - Features of early and late recurrence versus de novo metastatic ccRCC: Findings from JAVELIN Renal 101.
Journal of Clinical Oncology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Moshe Talpaz, MD
University of Michigan
William Herman, MD
University of Michigan
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”